Potential Site to Direct Selective Compounds in the Triosephosphate Isomerase for the Development of New Drugs

In the pharmaceutical industry, the development of selective drugs to an enzyme or the repositioning of commercial drugs, today, is booming. The glycolytic enzyme triosephosphate isomerase (TIM) has been used as a therapeutic target for the development of new drugs against various pathogenic organisms. Therefore, saving resources in the development of new drugs, by directing the interaction of pharmacological compounds to an interaction site with a high probability to be selective, represents an opportunity for researchers.